Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.45 |
| ▸ | NOS2 | P35228 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527105 | 0.78 | FFAR1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4630923 | 0.78 | FFAR1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL25200094 | 0.77 | FFAR1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL39723 | 0.77 | FFAR1 (0.44) | LOX | |
| SCHEMBL19401536 | 0.77 | IDO1 (0.32) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3645150 | 0.77 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL17478024 | 0.76 | TYK2 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL18568712 | 0.76 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL29304988 | 0.76 | NOS3 (0.44) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL3498257 | 0.74 | ASIC3 (0.54) | NOS3NOS2NOS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016055982-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2016-04-14 | — | — | WO | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | NOS3 296/4885NOS2 198/4885NOS1 276/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | NOS3 296/4885NOS2 198/4885NOS1 276/4885 |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | NOS3 4352/4885NOS2 4666/4885NOS1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.